Daniel Petrylak, MD is recognized as an international leader in the field of urology and a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney, and testicular cancer. He is currently a Professor of Medicine and Urology, a Co-Director of the Signal Transduction Program, and Co-Leader of Cancer Signalling Networks at Yale University Cancer Center in New Haven, CT.
Prof. Petrylak earned his MD from Case Western Reserve University School of Medicine in Cleveland, OH, before completing a residency in internal medicine at Albert Einstein College of Medicine/Jacobi Medical Center and a fellowship at Memorial Sloan Kettering Cancer Center in New York, NY.
Prof. Petrylak has served on the program committees for the American Urological Association and for the American Society of Clinical Oncology, and he has served as a committee member for the Devices and Immunologicals section of the FDA.
Speaking on novel chemotherapeutic agents for the treatment of genitourinary cancers
Prof. Petrylak is an active researcher in the field of genitourinary cancers, having authored more than 100 peer-reviewed articles published in renowned journals such as the Journal of Clinical Oncology and the New England Journal of Medicine. He has served as the principal investigator (PI) or co-PI on several SWOG clinical trials for genitourinary cancers, most notably serving as the PI for the randomized trial which led to the FDA’s approval of docetaxel for the treatment of hormone refractory prostate cancer.